Techfields Pharma


Clinical-stage pharmaceutical company developing prodrugs and a transdermal delivery platform to enable rapid tissue penetration of approved small molecules and biologics. The approach aims to increase local bioavailability, reduce systemic dose and toxicity, and enable targeted delivery across biological barriers (skin, blood-brain, cartilage). The company has an active pipeline spanning preclinical to Phase 3 and has received regulatory designations for its lead program.

Industries

biotechnology
medical
pharmaceutical

Nr. of Employees

small (1-50)

Techfields Pharma

Princeton, New Jersey, United States, North America


Products

X0002

Lead prodrug program being developed for pain associated with osteoarthritis (knee and back); clinical program includes Phase 3 and has received Fast Track designation and special protocol assessment.

TF0023

Program targeting hyperinflammatory states related to COVID-19 complications; listed among clinical programs in the company's pipeline.

Early-stage pipeline programs (examples: TF0066, TF0062, TF0068)

Preclinical / early-development prodrug programs targeting neuropathic pain, depression, anti-obesity, and Parkinson’s disease.


Services

Sponsored research and licensing collaborations

Scientific partnerships including sponsored research and licensing to apply transdermal prodrug technology to therapeutic candidates.

Expertise Areas

  • Transdermal drug delivery
  • Prodrug design and development
  • Topical spray/mist formulation
  • Preclinical pharmacokinetics and biodistribution
  • Show More (3)

Key Technologies

  • Transdermal delivery platforms
  • Prodrug chemistry and synthesis
  • Topical spray-mist formulations
  • Targeted tissue penetration techniques
  • Show More (2)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.